Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Torasemide 20mg tablets
0202020U0AAAFAF
|
Torasemide | Torasemide | Cardiovascular System | No data available |
|
Tracleer 125mg tablets
0205010U0BBABAB
|
Tracleer | Bosentan | Cardiovascular System | No data available |
|
Tracleer 62.5mg tablets
0205010U0BBAAAA
|
Tracleer | Bosentan | Cardiovascular System | No data available |
|
Trandate 100mg/20ml solution for injection ampoules
0204000I0BCAEAA
|
Trandate | Labetalol hydrochloride | Cardiovascular System | No data available |
|
Trandolapril 2mg/5ml oral suspension
0205051U0AAAGAG
|
Trandolapril | Trandolapril | Cardiovascular System | No data available |
|
Tranexamic acid 100mg/5ml oral solution
0211000P0AAAQAQ
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 150mg/5ml oral solution
0211000P0AABFBF
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 1g granules sachets
0211000P0AABGBG
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 1g/5ml oral solution
0211000P0AAAJAJ
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 2.5g/5ml oral solution
0211000P0AAAKAK
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 225mg/5ml oral solution
0211000P0AABABA
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 240mg/5ml oral solution
0211000P0AAAZAZ
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 25mg/5ml oral solution
0211000P0AAAUAU
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 300mg/5ml oral solution
0211000P0AAARAR
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 350mg/5ml oral solution
0211000P0AAAWAW
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 400mg/5ml oral solution
0211000P0AAANAN
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Tranexamic acid 425mg/5ml oral solution
0211000P0AAAXAX
|
Tranexamic acid | Tranexamic acid | Cardiovascular System | No data available |
|
Trasicor 20mg tablets
0204000N0BFAAAB
|
Trasicor | Oxprenolol hydrochloride | Cardiovascular System | No data available |
|
Trasicor 40mg tablets
0204000N0BFABAC
|
Trasicor | Oxprenolol hydrochloride | Cardiovascular System | No data available |
|
Trasicor 80mg tablets
0204000N0BFACAD
|
Trasicor | Oxprenolol hydrochloride | Cardiovascular System | No data available |
|
Trasidrex modified-release tablets
0204000Y0BBAAAA
|
Trasidrex | Co-prenozide (Oxprenolol hydrochloride/cyclopenthiazide) | Cardiovascular System | No data available |
|
Trasylol 1,000,000 Kallikrein inactivator units/100ml inf
0211000H0BBAFAF
|
Trasylol | Aprotinin | Cardiovascular System | No data available |
|
Trasylol 2,000,000 Kallikrein inactivator units/200ml inf
0211000H0BBAGAG
|
Trasylol | Aprotinin | Cardiovascular System | No data available |
|
Trasylol 500,000 Kallikrein inactivator units/50ml inf vials
0211000H0BBAEAE
|
Trasylol | Aprotinin | Cardiovascular System | No data available |
|
Tredaptive 1000mg/20mg modified-release tablets
0212000AEBBAAAA
|
Tredaptive | Nicotinic acid/laropiprant | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.